Datametrex NR ON Cash Agree wholeheartedly with the sentiments expressed thus far and would only add that cash on hand is even more relevant to ScreenPro.
Datametrex has a clear vision and developments/contracts that will see it expand and generate significant revenues post covid (end of 2022???). SCRN, on the other hand, needs to, and I believe will, diversify to move beyond covid, even in the world of testing. Imho it will be important at some time in the future for them to chart their own course, independent of DM ....which I again believe they will do.
In the meantime covid testing revenues (profits) that must be increasing significantly, based on the Datametrex NR, will be the catalyst for this diversification. As Morningstar's Fair Value sp still sits at $.07 today and the shorterm to longterm moving averages are steady at BUY things are looking up if the sp could sustainably bust free of $.03.
GLTE!!!